Life Extension Skin Care Sale

Leukemia References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Xie Y, Davies SM. et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer . 2003 May 1;97(9):2229-35.
  2. Call TG, Noel P. et al. Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc . 1994 Apr;69(4):315-22.
  3. Cartwright RA, Gurney KA. et al. Sex ratios and the risks of haematological malignancies. Br J Haematol . 2002 Sep;118(4):1071-7.
  4. McNeil DE, Cote TR, et al. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol. 2002 Dec;39(6):554-7.
  5. McNeil DE, Cote TR, et al. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol. 2002 Dec;39(6):554-7.
  6. Schoch C, Kern W. et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood . 2001 Dec 1;98(12):3500.
  7. Greaves MF. Biological models for leukaemia and lymphoma. IARC Sci Publ . 2004;(157):351-72.
  8. Irons RD, Stillman WS. The process of leukemogenesis. Environ Health Perspect . 1996 Dec;104 Suppl 6:1239-46.
  9. Alter BP. Cancer in Fanconi anemia, 1927-2001. Cancer. 2003 Jan 15;97(2):425-40.
  10. Bischof O, Kim SH. et al. Regulation and localization of the Bloom syndrome protein in response to DNA damage. J Cell Biol . 2001 Apr 16;153(2):367-80.
  11. Fong CT, Brodeur GM. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet . 1987 Sep;28(1):55-76.
  12. Fenech MF, Dreosti IE. et al. Folate, vitamin B12, homocysteine status and chromosome damage rate in lymphocytes of older men. Carcinogenesis . 1997 Jul;18(7):1329-36.
  13. Russell RM. The aging process as a modifier of metabolism. Am J Clin Nutr . 2000 Auga;72(2 Suppl):529S-32S.
  14. Esposito D, Fassina G. et al. Chromosomes of older humans are more prone to aminopterine-induced breakage. Proc Natl Acad Sci U S A . 1989 Feb;86(4):1302-6.
  15. Mendoza-Nunez VM, Retana-Ugalde R. et al. DNA damage in lymphocytes of elderly patients in relation with total antioxidant levels. Mech Ageing Dev . 1999 Apr 1;108(1):9-23.
  16. Ames BN, Shigenaga MK. et al. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7915-22.
  17. Ames BN. Micronutrients prevent cancer and delay aging. Toxicol Lett. 1998 Dec 28;102-103:5-18.
  18. Ames BN. Cancer prevention and diet: help from single nucleotide polymorphisms. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12216-8.
  19. Skibola CF, Smith MT. et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood . 2002 May 15;99(10):3786-91.
  20. Wickramasinghe SN, Fida S. Bone marrow cells from vitamin B12- and folate-deficient patients misincorporate uracil into DNA. Blood . 1994 Mar 15;83(6):1656-61.
  21. Visani G, Baravelli S. et al. Slimming diet and the development of acute leukemia: a possible relationship? Report of three cases. Leuk Lymphoma . 1997 Jun;26(1-2):181-3.
  22. McDonald TA, Holland NT. et al. Hypothesis: phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia. Leukemia . 2001 Jan;15(1):10-20.
  23. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta . 1998 Oct 1;1400(1-3):233-55.
  24. Kaldor JM, Day NE. et al. Leukemia following Hodgkin's disease. N Engl J Med . 1990 Jan 4;322(1):7-13.
  25. Smith MA, McCaffrey RP. et al. The secondary leukemias: challenges and research directions. J Natl Cancer Inst . 1996 Apr 3;88(7):407-18.
  26. Hawkins MM. Secondary leukaemia after epipodophyllotoxins. Lancet . 1991 Nov 30;338(8779):1408.
  27. Pedersen-Bjergaard J, Daugaard G. et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet . 1991 Aug 10;338(8763):359-63.
  28. Yamauchi T, Shirasaki H. et al. Pure red cell aplasia developing into myeloproliferation with myelodysplasia and subsequent leukemia after cyclosporin A therapy. Int J Hematol . 2002 Jun;75(5):514-8.
  29. Kamada N, Tanaka K. et al. Chromosome aberrations and transforming genes in leukemic and non-leukemic patients with a history of atomic bomb exposure. Princess Takamatsu Symp . 1987;18:125-34.
  30. Archer VE. Association of nuclear fallout with leukemia in the United States. Arch Environ Health . 1987 Sep;42(5):263-71.
  31. Johnson CJ. Cancer incidence in an area of radioactive fallout downwind from the Nevada Test Site. JAMA . 1984 Jan 13;251(2):230-6.
  32. Ichimaru M, Tomonaga M. et al. Atomic bomb and leukemia. J Radiat Res (Tokyo) . 1991 Dec;32 Suppl 2:14-9.
  33. Noshchenko AG, Zamostyan PV. et al. Radiation-induced leukemia risk among those aged 0-20 at the time of the Chernobyl accident: a case-control study in the Ukraine. Int J Cancer . 2002 Jun 1;99(4):609-18.
  34. Tilyou SM. BEIR V report. Experts urge cautious interpretation of higher risk estimates. J Nucl Med . 1990 Apr;31(4):13A-9A.
  35. Austin H, Delzell E. et al. Benzene and leukemia. A review of the literature and a risk assessment. Am J Epidemiol . 1988 Mar;127(3):419-39.
  36. Rinsky RA, Young RJ. et al. Leukemia in benzene workers. Am J Ind Med . 1981;2(3):217-45.
  37. Meinert R, Schuz J. et al. Leukemia and non-Hodgkin's lymphoma in childhood and exposure to pesticides: results of a register-based case-control study in Germany. Am J Epidemiol . 2000 Apr 1;151(7):639-46.
  38. Sandler DP. Recent studies in leukemia epidemiology. Curr Opin Oncol . 1995 Jan;7(1):12-8.
  39. Rauscher GH, Shore D. et al. Hair dye use and risk of adult acute leukemia. Am J Epidemiol . 2004 Jul 1;160(1):19-25.
  40. Korte JE, Hertz-Picciotto I. et al. The contribution of benzene to smoking-induced leukemia. Environ Health Perspect . 2000 Apr;108(4):333-9.
  41. Sandler DP, Shore DL. et al. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst . 1993 Dec 15;85(24):1994-2003.
  42. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol . 1997;15:15-37.
  43. Chatta GS, Dale DC. Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. Drugs Aging . 1996 Jul;9(1):37-47.
  44. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs . 2002;62 Suppl 1:1-15.
  45. Lyman GH, Kuderer N. et al. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control . 2003 Nov;10(6):487-99.
  46. Kennedy DD, Tucker KL. et al. Low antioxidant vitamin intakes are associated with increases in adverse effects of chemotherapy in children with acute lymphoblastic leukemia. Am J Clin Nutr . 2004 Jun;79(6):1029-36.
  47. Gajate C, An F. et al. Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/. Clin Cancer Res . 2003 Apr;9(4):1535-45.
  48. Featherstone C, Delaney G. et al. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence. Cancer . 2005 Jan 15;103(2):393-401.
  49. Peiffert D, Hoffstetter S. [Radiotherapy in leukemia excluding total body irradiation]. Cancer Radiother . 1999 Mar;3(2):174-80.
  50. McFarland JT, Kuzma C. et al. Palliative irradiation of the spleen. Am J Clin Oncol . 2003 Apr;26(2):178-83.
  51. Guilhot F, Roy L. et al. Interferon therapy in chronic myelogenous leukemia. Hematol Oncol Clin North Am . 2004 Jun;18(3):585-603, viii.
  52. Zinzani PL, Levrero MG. et al. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Haematologica . 1994 Jan;79(1):55-60.
  53. Sacchi S, Russo D. et al. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). Haematologica . 1997 Jan;82(1):106-21.
  54. Zheng A, Savolainen ER. et al. All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia. Leuk Res . 1996 Mar;20(3):243-8.
  55. Isidori A, Bonifazi F. et al. Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. Haematologica . 2005 Jan;90(1):139-41.
  56. Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant . 2003 May;31(9):731-8.
  57. Reiffers J, Stoppa AM. et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia . 1996 Dec;10(12):1874-82.
  58. Podar K, Anderson KC. The pathophysiological role of VEGF in hematological malignancies: therapeutic implications. Blood . 2004 Oct 7.
  59. Ferrajoli A, Manshouri T. et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res . 2001 Apr;7(4):795-9.
  60. Bieker R, Padro T. et al. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res . 2003 Nov 1;63(21):7241-6.
  61. Aguayo A, Kantarjian H. et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000 Sep 15;96(6):2240-5.
  62. Fayad L, Keating MJ. et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood . 2001 Jan 1;97(1):256-63.
  63. Quintas-Cardama A, Kantarjian H. et al. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer . 2004 Jun 15;100(12):2592-7.
  64. Eubank TD, Roberts R. et al. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity . 2004 Dec;21(6):831-42.
  65. Morecki S, Revel-Vilk S. et al. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2. Cancer Immunol Immunother . 1992;35(6):401-11.
  66. Balaian L, Ball ED. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies. Leuk Res . 2004 Aug;28(8):821-9.
  67. Feldman EJ. Monoclonal antibody therapy in acute myeloid leukemia. Curr Hematol Rep . 2003 Jan;2(1):73-7.
  68. Ritz J, Schlossman SF. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood . 1982 Jan;59(1):1-11.
  69. Lin TS, Moran M. et al. Antibody therapy for chronic lymphocytic leukemia: a promising new modality. Hematol Oncol Clin North Am . 2004 Aug;18(4):895-x.
  70. Cervetti G, Galimberti S. et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol . 2004 Dec;73(6):412-7.
  71. Lee JJ, Kook H. et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apheresis . 2004a;19(2):66-70.
  72. Biganzoli L, Untch M, et al. Neulasa (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol. 2004 Jun;31(3 Suppl 8):27-34.
  73. Itala M, Pelliniemi TT. et al. Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections. Leuk Lymphoma . 1998 Dec;32(1-2):165-74.
  74. Komrokji RS, Lyman GH. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther . 2004 Dec;4(12):1897-910.
  75. Biganzoli L, Untch M, et al. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol. 2004 Jun;31(3 Suppl 8):27-34.
  76. Maisnar V, Chroust K. Treatment of associated anemia in different hematological disorders with epoetin alpha. Neoplasma . 2004;51(5):379-84.
  77. Quirt I, Robeson C, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 2001 Nov 1;19(21):4126-34.
  78. Baroni S, Scribano D. et al. Lipids and lipoproteins in acute lymphoblastic leukaemia (ALL). Leuk Res . 1994 Aug;18(8):643-4.
  79. Baroni S, Scribano D. et al. Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia. Acta Haematol . 1996;96(1):24-8.
  80. Moschovi M, Trimis G. et al. Serum lipid alterations in acute lymphoblastic leukemia of childhood. J Pediatr Hematol Oncol . 2004 May;26(5):289-93.
  81. Fernandez C, Lobo Md Mdel V. et al. Cholesterol is essential for mitosis progression and its deficiency induces polyploid cell formation. Exp Cell Res . 2004 Oct 15;300(1):109-20.
  82. Everaus H. Hormones and immune responsiveness in chronic lymphocytic leukemia. Leuk Lymphoma . 1992 Dec;8(6):483-9.
  83. Singh JN, Chansouria JP. et al. Blood bioamines, cortisol and aminoacid levels in leukemic patients. Indian J Cancer . 1989 Dec;26(4):222-6.
  84. Everaus H, Luik E. et al. Active and indolent chronic lymphocytic leukaemia--immune and hormonal peculiarities. Cancer Immunol Immunother . 1997 Oct;45(2):109-14.
  85. raghi-Niknam M, Liang B. et al. Modulation of immune dysfunction during murine leukaemia retrovirus infection of old mice by dehydroepiandrosterone sulphate (DHEAS). Immunology . 1997 Mar;90(3):344-9.
  86. Inserra P, Zhang Z. et al. Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice. Proc Soc Exp Biol Med . 1998 May;218(1):76-82.
  87. Catalina F, Milewich L. et al. Dietary dehydroepiandrosterone inhibits bone marrow and leukemia cell transplants: role of food restriction. Exp Biol Med (Maywood ) . 2003 Dec;228(11):1303-20.
  88. Uozumi K, Uematsu T. et al. Serum dehydroepiandrosterone and DHEA-sulfate in patients with adult T-cell leukemia and human T-lymphotropic virus type I carriers. Am J Hematol . 1996 Nov;53(3):165-8.
  89. Patel D, Shukla, S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol. 2007;30(1):233-45.
  90. Wang IK, et al. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 1999a Oct;35(10):1517-25.
  91. Budhraja A, Gao N, Zhang Z, et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther. 2012 Jan;11(1):132-42.
  92. Takahashi T, et al. Structure-activity relationships of flavonoids and the induction of granulocytic- or monocytic-differentiation in HL60 human myeloid leukemia cells. Biosci Biotechnol Biochem 1998 Nov;62(11):2199-204.
  93. Kawaii S, et al. Effect of citrus flavonoids on HL-60 cell differentiation. Anticancer Res 1999 Mar-Apr; 19(2A):1261-9.
  94. Boege F, et al. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase. J Biol Chem 1996 Jan 26;271(4):2262-70.
  95. Chu DT, Lepe-Zuniga J, Wong WL, LaPushin R, Mavligit GM. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J Clin Lab Immunol. 1988 Aug;26(4):183-7.
  96. Cho WC, Leung KN. In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol. 2007a Aug 15;113(1):132-41.
  97. Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett. 2007b Jul 8;252(1):43-54
  98. Huang LH, Yan QJ, Kopparapu NK, Jiang ZQ, Sun Y. Astragalus membranaceus lectin (AML) induces caspase-dependent apoptosis in human leukemia cells. Cell Prolif. 2012 Feb;45(1):15-21.
  99. Bakuradze T, Boehm N, Janzowski C, et al. Antioxidant-rich coffee reduces DNA damage, elevates glutathione status and contributes to weight control: results from an intervention study. Mol Nutr Food Res. 2011 May;55(5):793-7.
  100. Hoelzl C, Knasmuller S, Wagner KH, et al. Instant coffee with high chlorogenic acid levels protects humans against oxidative damage of macromolecules. Mol Nutr Food Res. 2010 Dec;54(12):1722-33.
  101. Misik M, Hoelzl C, Wagner KH, et al. Impact of paper filtered coffee on oxidative DNA-damage: results of a clinical trial. Mutat Res. 2010 Oct 13;692(1-2):42-8.
  102. Jin UH, Lee JY, Kang SK, et al. A phenolic compound, 5-caffeoylquinic acid (chlorogenic acid), is a new type and strong matrix metalloproteinase-9 inhibitor: isolation and identification from methanol extract of Euonymus alatus. Life Sci. 2005 Oct 14;77(22):2760-9.
  103. Belkaid A, Currie JC, Desgagnés J, et al. The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression. Cancer Cell Int. 2006 Mar 27;6:7.
  104. Bandyopadhyay G, Biswas T, Roy KC, et al. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood. 2004 Oct 15;104(8):2514-22.
  105. Srivastava MD, Ambrus JL. Effect of 1,25(OH)2 Vitamin D3 analogs on differentiation induction and cytokine modulation in blasts from acute myeloid leukemia patients. Leuk Lymphoma . 2004 Oct;45(10):2119-26.
  106. Singh V, Kharb S. et al. Serum vitamin E in chronic myeloid leukaemia. J Assoc Physicians India . 2000 Feb;48(2):201-3.
  107. Sokoloski JA, Hodnick WF. et al. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-kappaB. Leukemia . 1997 Sep;11(9):1546-53.
  108. Miyazawa K, Yaguchi M. et al. Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia . 2001 Jul;15(7):1111-7.
  109. Yaguchi M, Miyazawa K. et al. Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid. Leukemia . 1997 Jun;11(6):779-87.
  110. Carlo-Stella C, Regazzi E. et al. Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. Br J Haematol . 1996b Jun;93(3):551-7.
  111. Carlo-Stella C, Dotti G. et al. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood . 1996a Oct 15;88(8):3091-100.
  112. Lee R, Kim YJ. et al. The selective effect of genistein on the toxicity of bleomycin in normal lymphocytes and HL-60 cells. Toxicology . 2004b Feb 15;195(2-3):87-95.
  113. Lian F, Li Y. et al. p53-independent apoptosis induced by genistein in lung cancer cells. Nutr Cancer . 1999;33(2):125-31.
  114. Arbiser JL, Klauber N. et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med . 1998 Jun;4(6):376-83.
  115. Jee SH, Shen SC. et al. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol . 1998 Oct;111(4):656-61.
  116. Xu YX, Pindolia KR. et al. Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol . 1997;11(1):49-62.
  117. Lee YK, Bone ND. et al. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood . 2004c Aug 1;104(3):788-94.
  118. Li HC, Yashiki S. et al. Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res . 2000 Jan;91(1):34-40.
  119. Lung HL, Ip WK. et al. Comparative study of the growth-inhibitory and apoptosis-inducing activities of black tea theaflavins and green tea catechin on murine myeloid leukemia cells. Int J Mol Med . 2004 Mar;13(3):465-71.
  120. De CR, Liao JK. et al. Fatty acid modulation of endothelial activation. Am J Clin Nutr . 2000 Jan;71(1 Suppl):213S-23S.
  121. Purasiri P, Mckechnie A. et al. Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids. Immunology . 1997 Oct;92(2):166-72.
  122. Liu QY, Tan BK. Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines. Life Sci . 2000;67(10):1207-18.
  123. Gillis RC, Daley BJ. et al. Eicosapentaenoic acid and gamma-linolenic acid induce apoptosis in HL-60 cells. J Surg Res . 2002 Sep;107(1):145-53.
  124. Harries M, O'Donnell A. et al. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. Br J Cancer . 2004 Nov 1;91(9):1651-5.
  125. Hagen TM, Ingersoll RT. et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J . 1999 Feb;13(2):411-8.
  126. Lykkesfeldt J, Hagen TM. et al. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes--reversal with (R)-alpha-lipoic acid supplementation. FASEB J . 1998 Sep;12(12):1183-9.
  127. Sen CK, Sashwati R. et al. Fas mediated apoptosis of human Jurkat T-cells: intracellular events and potentiation by redox-active alpha-lipoic acid. Cell Death Differ . 1999 May;6(5):481-91.
  128. Sen CK, Roy S. et al. Regulation of cellular thiols in human lymphocytes by alpha-lipoic acid: a flow cytometric analysis. Free Radic Biol Med . 1997;22(7):1241-57.
  129. Kang HK, Suh JH. et al. Induction of the differentiation of HL-60 promyelocytic leukemia cells by L-ascorbic acid. Free Radic Res . 2003 Jul;37(7):773-9.
  130. Park S, Han SS. et al. L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. Int J Biochem Cell Biol . 2004 Nov;36(11):2180-95.
  131. Huang ME, Ye YC. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood . 1988 Aug;72(2):567-72.
  132. Mann G, Reinhardt D. et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol . 2001 Jul;80(7):417-22.
  133. Manley PW, Cowan-Jacob SW. et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer . 2002 Sep;38 Suppl 5:S19-S27.
  134. Nakajima M, Toga W. Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor. Nippon Yakurigaku Zasshi . 2003 Dec;122(6):482-90.
  135. Aggarwal BB, Kumar A. et al. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003 Jan;23(1A):363-98.
  136. Pugliese PT, Jordan K. et al. Some biological actions of alkylglycerols from shark liver oil. J Altern Complement Med . 1998;4(1):87-99.
  137. Hassan HT. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy. Leuk Res . 2004 Jul;28(7):667-71.
  138. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate . 2001 Feb 1;46(2):98-107.
  139. Hurley MM, Marcello K. et al. Signal transduction by basic fibroblast growth factor in rat osteoblastic Py1a cells. J Bone Miner Res . 1996 Sep;11(9):1256-63.
  140. Asou H, Koshizuka K. et al. Resveratrol, a natural product derived from grapes, is a new inducer of differentiation in human myeloid leukemias. Int J Hematol . 2002 Jun;75(5):528-33.
  141. Estrov Z, Shishodia S. et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood . 2003 Aug 1;102(3):987-95.
  142. Xu B, Monsarrat B. et al. Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells. Fundam Clin Pharmacol . 2004 Apr;18(2):171-80.
  143. Ahmed N, Laverick L. et al. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells. Anticancer Res. 2001 Sep;21(5):3519-23.
  144. Kang JH, Song KH, Woo JK, et al. Ginsenoside Rp1 from Panax ginseng exhibits anti-cancer activity by down-regulating of the IGF-1R/Akt pathway in breast cancer cells. Plant Foods Hum Nutr. 2011;66(3):298-305.
  145. Lee SJ, Ko WG, Kim JH, et al. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem Pharmacol. 2000 Sep 1;60(5):677-85.
  146. Nguyen HT, Song GY, Kim JA, et al. Dammarane-type saponins from the flower buds of Panax ginseng and their effects on human leukemia cells. Bioorg Med Chem Lett. 2010 Jan 1;20(1):309-14.
  147. Kim SH, Cho SS, Simkhada JR, et al. Enhancement of 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced HL-60 leukemia cell differentiation by Panax ginseng. Biosci Biotechnol Biochem. 2009 May;73(5):1048-53.
  148. Koda K, Miyazaki M et al. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.Int J Oncol . 2003;23(1):165-72.
  149. Noguchi K, Tanimura H et al. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.Anticancer Res . 1995;15(2):255-8.
  150. Yokoe T, Iino Y et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.Anticancer Res . 1997;17(4A):2815-8.
  151. Zhang H, Morisaki T et al. Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.Clin Exp Metastasis . 2000;18(4):343-52.
  152. Ohwada S, Ogawa T, Makita F, et al. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncol Rep. 2006 Apr;15(4):861-8.
  153. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002 May;22(3):1737-54.
  154. Garcia-Lora A, Pedrinaci S, Garrido F. Protein-bound polysaccharide K and interleukin-2 regulate difference nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunol Immunother. 2001 Jun;50(4):191-8.
  155. Pedrinaci S, Algarra I, Garrido F. Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res. 1999;29(4):135-40.
  156. Lau CB, Ho CY, Kim CF et al. Cytotoxic activities of Coriolus versicolor (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis. Life Sci. 2004 Jul 2;75(7):797-808.
  157. Ho CY, Kim CF, Leung KN et al. Coriolus versicolor (Yunzhi) extract attenuates growth of human leukemia xenografts and induces apoptosis through the mitochondrial pathway. Oncol Rep. 2006 Sep;16(3):609-16.
  158. Hirahara N, Edamatsu T, Fujieda A et al. Protein-bound Polysaccharide-K (PSK) Induces Apoptosis via p38 Mitogen-activated Protein Kinase Pathway in Promyelomonocytic Leukemia HL-60 Cells. Anticancer Res. 2012 Jul;32(7):2631-7.
  159. Bao X, Liu C, Fang J, Li X. Structural and immunological studies of a major polysaccharide from spores of Ganoderma lucidum (Fr.) Karst. Carbohydr Res. 2001 May 8;332(1):67-74.
  160. Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med. 2011;39(1):15-27.
  161. Yeh CH, Chen HC, Yang JJ, Chuang WI, Sheu F. Polysaccharides PS-G and protein LZ-8 from Reishi (Ganoderma lucidum) exhibit diverse functions in regulating murine macrophages and T lymphocytes. J Agric Food Chem. 2010 Aug 11;58(15):8535-44.
  162. Cao LZ, Lin ZB. Regulation on maturation and function of dendritic cells by Ganoderma lucidum polysaccharides. Immunol Lett. 2002 Oct 1;83(3):163-9.
  163. Lai CY, Hung JT, Lin HH, et al. Immunomodulatory and adjuvant activities of a polysaccharide extract of Ganoderma lucidum in vivo and in vitro. Vaccine. 2010 Jul 12;28(31):4945-54.
  164. Jan RH, Lin TY, Hsu YC, et al. Immuno-modulatory activity of Ganoderma lucidum-derived polysacharide on human monocytoid dendritic cells pulsed with Der p 1 allergen. BMC Immunol. 2011;12:31.
  165. Ji Z, Tang Q, Zhang J, Yang Y, Liu Y, Pan YJ. Immunomodulation of bone marrow macrophages by GLIS, a proteoglycan fraction from Lingzhi or Reishi medicinal mushroom Ganoderma lucidium (W.Curt.:Fr.) P. Karst. Int J Med Mushrooms.2011;13(5):441-8.
  166. Chan WK, Lam DT, Law HK, et al. Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy. J Altern Complement Med. 2005 Dec;11(6):1047-57.
  167. Chu CL, Chen Dz C, Lin CC. A novel adjuvant Ling Zhi-8 for cancer DNA vaccines. Hum Vaccin. 2011 Nov;7(11):1161-4.
  168. Lin CC, Yu YL, Shih CC, et al. A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. Cancer Immunol Immunother. 2011 Jul;60(7): 1019-27.
  169. Zhu XL, Liu JH, Li WD, Lin ZB. Promotion of myelopoiesis in myelosuppressed mice by Ganoderma lucidum polysaccharides. Front Pharmacol. 2012;3:20.
  170. Zhu XL, Chen AF, Lin ZB. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol. 2007 May 4;111(2):219-26.
  171. Wang PY, Zhu XL, Lin ZB. Antitumor and immunomodulatory effects of polysaccharides from broken-spore of Ganoderma lucidum. Front Pharmacol. 2012;3:135.
  172. Jeurink PV, Noguera CL, Savelkoul HF, Wichers HJ. Immunomodulatory capacity of fungal proteins on the cytokine production of human peripheral blood mononuclear cells. Int Immunopharmacol. 2008 Aug;8(8):1124-33.
  173. Wang SY, Hsu ML, Hsu HC, et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer. 1997 Mar 17;70(6):699-705.
  174. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem. 2000 Jul;7(7):715-29.
  175. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003 Aug;32(3):201-15.
  176. Muller CI, Kumagai T, O’Kelly J, Seeram NP, Heber D, Koeffler HP. Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res. 2006 Jul;30(7):841-8.
  177. Lu H, Uesaka T, Katoh O, Kyo E, Watanabe H. Prevention of the development of preneoplastic lesions, aberrant crypt foci, by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male F344 rats. Oncol Rep. 2001 Nov- Dec;8(6):1341-5.
  178. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. Prevention of development of N,N’-dimethylhydrazine-induced colon tumors by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male ICR mice. Int J Mol Med. 2002 Feb;9(2):113-7.
  179. Oka S, Tanaka S, Yoshida S, et al. A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci. 2010 Mar;59(1):1-6.
  180. Joseph S, Sabulal B, George V, Antony KR, Janardhanan KK. Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum. Acta Pharm. 2011 Sep 1;61(3):335-42.
  181. BROHULT A. Effects of alkoxyglycerols and especially selachyl alcohol on the bone marrow in connexion with irradiation treatment and in leukaemia therapy. Nature . 1958 May 24;181(4621):1484-5.
  182. Wang H, Rajagopal S. et al. Differentiation-promoting effect of 1-O (2 methoxy) hexadecyl glycerol in human colon cancer cells. J Cell Physiol . 1999b Feb;178(2):173-8.
  183. Pedrono F, Martin B. et al. Natural alkylglycerols restrain growth and metastasis of grafted tumors in mice. Nutr Cancer . 2004;48(1):64-9.
  184. Zhang Y, Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin. 2007 Sep;28(9):1343-54.
  185. Nian H, Delage B, Ho E, et al. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ Mol Mutagen. 2009 Apr;50(3):213-21.
  186. Traka M, Gasper AV, Melchini A, et al. Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS One. 2008 Jul 2;3(7):e2568.
  187. Thejass P, Kuttan G. Augmentation of natural killer cell and antibody-dependent cellular cytotoxicity in BALB/c mice by sulforaphane, a naturally occurring isothiocyanate from broccoli through enhanced production of cytokines IL-2 and IFN-gamma. Immunopharmacol Immunotoxicol. 2006;28(3):443-57.
  188. Dinkova-Kostova AT. Phytochemicals as protectors against ultraviolet radiation: versatility of effects and mechanisms. Planta Med. 2008 Oct;74(13):1548-59.
  189. Lin LC, Yeh CT, Kuo CC, et al. Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function. J Agric Food Chem. 2012 Jul 18;60(28):7031-9.
  190. Moon DO, Kim MO, Kang SH, et al. Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Lett. 2009 Feb 8;274(1):132-42.
  191. Okuno M, Kojima S. et al. Retinoids in cancer chemoprevention. Curr Cancer Drug Targets . 2004 May;4(3):285-98.
  192. Skrede B, Lie SO. et al. Uptake and storage of retinol and retinyl esters in bone marrow of children with acute myeloid leukemia treated with high-dose retinyl palmitate. Eur J Haematol . 1994 Mar;52(3):140-4.
  193. Kerr PE, DiGiovanna JJ. From vitamin to Vesanoid: systemic retinoids for the new millennium. Med Health R I . 2001 Jul;84(7):228-31.
  194. Defacque H, Commes T. et al. Expression of Retinoid X Receptor alpha is increased upon monocytic cell differentiation. Biochem Biophys Res Commun . 1996 Mar 18;220(2):315-22.
  195. Elstner E, Linker-Israeli M. et al. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res . 1996 Aug 1;56(15):3570-6.
  196. Miyauchi J, Inatomi Y. et al. The in vitro effects of all-trans-retinoic acid and hematopoietic growth factors on the clonal growth and self-renewal of blast stem cells in acute promyelocytic leukemia. Leuk Res . 1997 Apr;21(4):285-94.
  197. Nakajima H, Kizaki M. et al. All-trans and 9-cis retinoic acid enhance 1,25-dihydroxyvitamin D3-induced monocytic differentiation of U937 cells. Leuk Res . 1996 Aug;20(8):665-76.
  198. Jenkins MY, Mitchell GV. et al. Dietary vitamin E and beta-carotene sources influence vitamin A and E storage in young rats fed marginal and adequate vitamin E. Nutr Cancer . 1999;34(2):235-41.
  199. St Claire MB, Kennett MJ. et al. Vitamin A toxicity and vitamin E deficiency in a rabbit colony. Contemp Top Lab Anim Sci . 2004 Jul;43(4):26-30.
  200. Su JL, Lin MT. et al. Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells. Carcinogenesis . 2005 Jan;26(1):1-10.
  201. Castello L, Tessitore L. Reservatol inhibits cell cycle progression in U937 cells. Oncol Rep . 2005 Jan;13(1):133-7.
  202. Aggarwal BB, Bhardwaj A. et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004 Sep;24(5A):2783-840.
  203. Gao X, Xu YX. et al. Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. J Nutr . 2002 Jul;132(7):2076-81.
  204. Thompson JR, Gerald PF. et al. Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case-control study. Lancet . 2001 Dec 8;358(9297):1935-40.
  205. Cohen IJ. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol . 2004 Mar;26(3):156-63.
  206. Kisliuk RL. Deaza analogs of folic acid as antitumor agents. Curr Pharm Des . 2003;9(31):2615-25.
  207. Haimov I, Lavie P. Melatonin - a chronobiotic and soporific hormone. Arch Gerontol Geriatr . 1997 Mar;24(2):167-73.
  208. El-Sokkary GH, Reiter RJ. et al. Melatonin supplementation restores cellular proliferation and DNA synthesis in the splenic and thymic lymphocytes of old rats. Neuro Endocrinol Lett . 2003 Jun;24(3-4):215-23.
  209. Conti A, Haran-Ghera N. et al. Role of pineal melatonin and melatonin-induced-immuno-opioids in murine leukemogenesis. Med Oncol Tumor Pharmacother . 1992;9(2):87-92.
  210. Granzotto M, Rapozzi V. et al. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res . 2001 Oct;31(3):206-13.
  211. Lissoni P, Bolis S. et al. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Res . 2000 May;20(3B):2103-5.
  212. Nir I, Weiss L. et al. The use of melatonin and co-treatment with autologous or allogeneic cells as a model for control of malignant beta-cell leukemia. Adv Exp Med Biol . 1999;460:407-9.
  213. Fiorenza AM, Branchi A. et al. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res . 2000;30(3):141-5.
  214. Cohen L, de MC. et al. Endocrine levels at the start of treatment are associated with subsequent psychological adjustment in cancer patients with metastatic disease. Psychosom Med . 2001 Nov;63(6):951-8.
  215. Barton JC, Poon MC. Coagulation testing of Hickman catheter blood in patients with acute leukemia. Arch Intern Med . 1986 Nov;146(11):2165-9.
  216. Anders O, Nagel HR. et al. [Blood coagulation factors and proteinase inhibitors in cytostatic therapy of acute leukemia]. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(5):769-80.
  217. Higuchi T, Shimizu T. et al. Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia. Hematol Oncol . 1997 Nov;15(4):209-17.
  218. Quirt I, Robeson C, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 2001 Nov 1;19(21):4126-34.
  219. Melo MB, Ahmad NN. et al. Mutations in the p53 gene in acute myeloid leukemia patients correlate with poor prognosis. Hematology . 2002 Feb;7(1):13-9.
  220. Nakano Y, Naoe T. et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol . 2000 Jul;65(1):23-31.
  221. Patlak M. Targeting leukemia: from bench to bedside. FASEB J . 2002 Mar;16(3):273.
  222. Vera P, Rohrlich P. et al. Contribution of single-photon emission computed tomography in the diagnosis and follow-up of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia. J Clin Oncol . 1999 Sep;17(9):2804-10.
  223. Bessmel'tsev SS, Abdulkadyrov KM. [The importance of sonography in the diagnosis of extramedullary hematopoietic foci in acute leukemia]. Vopr Onkol . 1991;37(11-12):1054-62.
  224. Saven A, Burian C. et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood . 1998 Sep 15;92(6):1918-26.
  225. Kakizoe T. Chemoprevention of cancer--focusing on clinical trials. Jpn J Clin Oncol . 2003 Sep;33(9):421-42.
  226. Meyskens FL, Jr., Kopecky KJ. et al. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res . 1995 Sep;19(9):605-12.
  227. Mellibovsky L, Diez A. et al. Long-standing remission after 25-OH D3 treatment in a case of chronic myelomonocytic leukaemia. Br J Haematol . 1993 Dec;85(4):811-2.
  228. Gescher A. Polyphenolic phytochemicals versus non-steroidal anti-inflammatory drugs: which are better cancer chemopreventive agents? J Chemother . 2004 Nov;16 Suppl 4:3-6.
  229. Laurie SA, Miller VA. et al. Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol . 2005 Jan;55(1):33-8.
  230. Pisters KM, Newman RA. et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol . 2001 Mar 15;19(6):1830-8.
  231. Anderson GD, Rosito G. et al. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol . 2003 Jun;43(6):643-8.
  232. Rock E, DeMichele A. Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr . 2003 Nov;133(11 Suppl 1):3785S-93S.
  233. Gonin JM, Nguyen H. et al. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol . 2003 Jul;16(4):522-34.
  234. Buckley R, Shewring B. et al. Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr . 2004 Sep;92(3):477-83.
  235. Johnson CD, Puntis M. et al. Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. Br J Surg . 2001 May;88(5):662-8.
  236. Huppert FA, Van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function. Cochrane Database Syst Rev . 2001;(2):CD000304.
  237. Walle T, Hsieh F. et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos . 2004 Dec;32(12):1377-82.
  238. Scagliotti GV, Shin DM. et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol . 2003 Apr 15;21(8):1556-61.